Genome-Wide Association Study in Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

English version České info

BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10⁻⁸, HR = 1.14, 95% CI: 1.09–1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10⁻⁸, HR = 1.27, 95% CI: 1.17–1.38) and 4q32.3 (rs4691139, P = 3.4×10⁻⁸, HR = 1.20, 95% CI: 1.17–1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2×10⁻⁴). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.

Vyšlo v časopise: Genome-Wide Association Study in Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genet 9(3): e32767. doi:10.1371/journal.pgen.1003212
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003212

Souhrn

Zdroje

1. AntoniouA, PharoahPD, NarodS, RischHA, EyfjordJE, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117–1130.

2. AntoniouAC, Chenevix-TrenchG (2010) Common genetic variants and cancer risk in Mendelian cancer syndromes. Curr Opin Genet Dev 20: 299–307 S0959-437X(10)00044-4 [pii];10.1016/j.gde.2010.03.010 [doi].

3. BeggCB, HaileRW, BorgA, MaloneKE, ConcannonP, et al. (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299: 194–201.

4. SimchoniS, FriedmanE, KaufmanB, Gershoni-BaruchR, Orr-UrtregerA, et al. (2006) Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A 103: 3770–3774.

5. CouchFJ, GaudetMM, AntoniouAC, RamusSJ, KuchenbaeckerKB, et al. (2012) Common cariants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 21: 645–657 1055-9965.EPI-11-0888 [pii];10.1158/1055-9965.EPI-11-0888 [doi].

6. RamusSJ, KartsonakiC, GaytherSA, PharoahPD, SinilnikovaOM, et al. (2010) Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 103: 105–116 djq494 [pii];10.1093/jnci/djq494 [doi].

7. RamusSJ, AntoniouAC, KuchenbaeckerKB, SoucyP, BeesleyJ, et al. (2012) Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat 33: 690–702 10.1002/humu.22025 [doi].

8. AntoniouAC, SpurdleAB, SinilnikovaOM, HealeyS, PooleyKA, et al. (2008) Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 82: 937–948.

9. AntoniouAC, SinilnikovaOM, McGuffogL, HealeyS, NevanlinnaH, et al. (2009) Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 18: 4442–4456 ddp372 [pii];10.1093/hmg/ddp372 [doi].

10. AntoniouAC, KartsonakiC, SinilnikovaOM, SoucyP, McGuffogL, et al. (2011) Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 20: 3304–3321 ddr226 [pii];10.1093/hmg/ddr226 [doi].

11. AntoniouAC, KuchenbaeckerKB, SoucyP, BeesleyJ, ChenX, et al. (2012) Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 14: R33 bcr3121 [pii];10.1186/bcr3121 [doi].

12. AntoniouAC, WangX, FredericksenZS, McGuffogL, TarrellR, et al. (2010) A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 42: 885–892 ng.669 [pii];10.1038/ng.669 [doi].

13. StevensKN, VachonCM, LeeAM, SlagerS, LesnickT, et al. (2011) Common breast cancer susceptibility loci are associated with triple negative breast cancer. Cancer Res 0008-5472.CAN-11-1266 [pii];10.1158/0008-5472.CAN-11-1266 [doi].

14. GaudetMM, KuchenbaeckerKB, VijaiJ, KleinRJ, KirchhoffT, et al. (2013) Identification of a BRCA2-specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genet 9: e1003173 doi:10.1371/journal.pgen.1003173.

15. RobertsonA, HillWG (1984) Deviations from Hardy-Weinberg proportions: sampling variances and use in estimation of inbreeding coefficients. Genetics 107: 703–718.

16. AntoniouAC, GoldgarDE, AndrieuN, Chang-ClaudeJ, BrohetR, et al. (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29: 1–11.

17. BarnesDR, LeeA, EastonDF, AntoniouAC (2012) Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. Genet Epidemiol 36: 274–291 10.1002/gepi.21620 [doi].

18. AntoniouAC, SinilnikovaOM, SimardJ, LeoneM, DumontM, et al. (2007) RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81: 1186–1200.

19. AminN, van DuijnCM, AulchenkoYS (2007) A genomic background based method for association analysis in related individuals. PLoS ONE 2: e1274 doi:10.1371/journal.pone.0001274.

20. LeuteneggerAL, PrumB, GeninE, VernyC, LemainqueA, et al. (2003) Estimation of the inbreeding coefficient through use of genomic data. Am J Hum Genet 73: 516–523 10.1086/378207 [doi];S0002-9297(07)62015-1 [pii].

21. BoosDD (1992) On generalised score tests. American Statistician 46: 327–333.

22. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661–678 nature05911 [pii];10.1038/nature05911 [doi].

23. AulchenkoYS, RipkeS, IsaacsA, van DuijnCM (2007) GenABEL: an R library for genome-wide association analysis. Bioinformatics 23: 1294–1296 btm108 [pii];10.1093/bioinformatics/btm108 [doi].

24. LangeK, WeeksD, BoehnkeM (1988) Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 5: 471–472.

25. AntoniouAC, CunninghamAP, PetoJ, EvansDG, LallooF, et al. (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98: 1457–1466.

26. MulliganAM, CouchFJ, BarrowdaleD, DomchekSM, EcclesD, et al. (2011) Common breast cancer susceptibility alleles are associated with tumor subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 13: R110 bcr3052 [pii];10.1186/bcr3052 [doi].

27. HowieB, MarchiniJ, StephensM (2011) Genotype imputation with thousands of genomes. G3 (Bethesda) 1: 457–470 10.1534/g3.111.001198 [doi];GGG_001198 [pii].

28. AntoniouAC, BeesleyJ, McGuffogL, SinilnikovaOM, HealeyS, et al. (2010) Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Res 70: 9742–9754 0008-5472.CAN-10-1907 [pii];10.1158/0008-5472.CAN-10-1907 [doi].

29. MavaddatN, BarrowdaleD, AndrulisIL, DomchekSM, EcclesD, et al. (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21: 134–147 1055-9965.EPI-11-0775 [pii];10.1158/1055-9965.EPI-11-0775 [doi].

30. GoodeEL, Chenevix-TrenchG, SongH, RamusSJ, NotaridouM, et al. (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42: 874–879 ng.668 [pii];10.1038/ng.668 [doi].

31. BojesenS, PooleyKA, JohnattySE, BeesleyJ, MichailidouK, et al. (2012) Multiple independent TERT variants associated with telomere length and risks of breast and ovarian cancer. Nat Genet In Press.

32. MichailidouK, HallP, Gonzalez-NeiraA, GhoussainiM, DennisJ, et al. (2012) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet In Press.

33. SladekR, RocheleauG, RungJ, DinaC, ShenL, et al. (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445: 881–885 nature05616 [pii];10.1038/nature05616 [doi].

34. Garcia-ClosasM, CouchFJ, LindstromS, MichailidouK, SchmidtMK, et al. (2012) Genome-wide association studies identify four ER-negative specific breast cancer risk loci. Nat Genet In Press.

35. AtwalGS, KirchhoffT, BondEE, MontagnaM, MeninC, et al. (2009) Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A 106: 10236–10241 0901298106 [pii];10.1073/pnas.0901298106 [doi].

36. CurtisC, ShahSP, ChinSF, TurashviliG, RuedaOM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346–352 nature10983 [pii];10.1038/nature10983 [doi].

37. LaurieNA, DonovanSL, ShihCS, ZhangJ, MillsN, et al. (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61–66 nature05194 [pii];10.1038/nature05194 [doi].

38. WadeM, WahlGM (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7: 1–11 7/1/1 [pii];10.1158/1541-7786.MCR-08-0423 [doi].

39. FairfaxBP, MakinoS, RadhakrishnanJ, PlantK, LeslieS, et al. (2012) Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet 44: 501–510 ng.2205 [pii];10.1038/ng.2205 [doi].

40. GeB, PokholokDK, KwanT, GrundbergE, MorcosL, et al. (2009) Global patterns of cis variation in human cells revealed by high-density allelic expression analysis. Nat Genet 41: 1216–1222 ng.473 [pii];10.1038/ng.473 [doi].

41. GrundbergE, AdoueV, KwanT, GeB, DuanQL, et al. (2011) Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. PLoS Genet 7: e1001279 doi:10.1371/journal.pgen.1001279.

42. StefanssonH, HelgasonA, ThorleifssonG, SteinthorsdottirV, MassonG, et al. (2005) A common inversion under selection in Europeans. Nat Genet 37: 129–137 ng1508 [pii];10.1038/ng1508 [doi].

43. BowenNJ, WalkerLD, MatyuninaLV, LoganiS, TottenKA, et al. (2009) Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics 2: 71 1755-8794-2-71 [pii];10.1186/1755-8794-2-71 [doi].

44. IkramMA, FornageM, SmithAV, SeshadriS, SchmidtR, et al. (2012) Common variants at 6q22 and 17q21 are associated with intracranial volume. Nat Genet 44: 539–544 ng.2245 [pii];10.1038/ng.2245 [doi].

45. Simon-SanchezJ, SchulteC, BrasJM, SharmaM, GibbsJR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308–1312 ng.487 [pii];10.1038/ng.487 [doi].

46. PharoahP, TsaiYY, RamusS, PhelanC, GoodeEL, et al. (2012) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet In Press.